Quarterly report pursuant to Section 13 or 15(d)

3. Significant Strategic Drug Development Collaborations - Related Parties

v3.4.0.3
3. Significant Strategic Drug Development Collaborations - Related Parties
3 Months Ended
Mar. 31, 2016
Significant Strategic Drug Development Collaborations - Related Parties  
Significant Strategic Drug Development Collaborations - Related Parties

The Company has entered into various research, development, license and supply agreements with Baxalta Incorporated (a spinoff of the biopharmaceuticals business from Baxter Healthcare SA and Baxter Healthcare Corporation), SynBio LLC (“SynBio”), Serum Institute of India (“Serum Institute”) and Pharmsynthez. The Company and its collaborative partners continue to engage in research and development activities with no resultant commercial products through March 31, 2016. No amounts were recognized as revenue related to these agreements during the three months ended March 31, 2016 or 2015.